Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PKNOX2 antisense RNA 1 (PKNOX2-AS1) is a long non-coding RNA situated opposite to the coding sequence of PKNOX2. Studies show that PKNOX2-AS1 can suppress the secretion of pro-inflammatory cytokines (like IL-1β, IL-6, IL-18, and TNF-α) and protect renal epithelial cells from damage and cell death induced by sepsis or inflammation. It achieves this by inhibiting NF-κB pathway activation and modulating chromatin structure, thus regulating gene expression at both transcriptional and post-transcriptional levels. This RNA molecule has no protein product and acts mainly through RNA-mediated mechanisms including miRNA sequestration and transcriptional modulation. Its downregulation is associated with increased susceptibility to inflammation-induced injury. Although research is at a preliminary stage, PKNOX2-AS1 is being considered for biomarker development and potential therapeutic intervention in conditions such as acute kidney injury and possibly cancer.
Modulates chromatin structure and cytokine gene expression; Acts as a sponge for microRNAs (miRNAs), potentially affecting pathways like NF-κB; Inhibits PI3K/AKT/mTOR signaling via regulatory mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PKNOX2 antisense RNA 1 (PKNOX2-AS1).